Jalaber, Carole
Puéchal, Xavier
Saab, Ines
Canniff, Emma
Terrier, Benjamin
Mouthon, Luc
Cabanne, Eglantine
Mghaieth, Sandra
Revel, Marie-Pierre
Chassagnon, Guillaume
Article History
Received: 27 June 2022
Accepted: 30 September 2022
First Online: 28 October 2022
Declarations
:
: This retrospective observational study was approved by our local ethics committee (CLEP Decision no AAA-2020-08044), which waived the need for patient consent.
: Not applicable.
: XP has been an investigator in academic studies of ANCA-associated vasculitis for which rituximab was provided by Roche Pharma. MPR reports personal fees from Boehringer Ingelheim, Bracco, Chiesi, and GE Healthcare; travel fees from Guerbet; and a research grant from the French Ministry of Health and the French Cancer Institute, outside the submitted work. G. C. reports personal fees from Chiesi and Gleamer outside the submitted work. None declared: C. J., I. S., Em. C., B. T., L. M., Eg. C., and S. M.